Xilio Therapeutics, Inc. Common Stock (XLO)

Price$7.70

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-35.35%

Price vs S&P 500 (4W)-0.51%

VGM Score73.10

Market Capitalization$48.73M

All Metrics

Book Value / Share (Quarterly)$12.55

P/TBV (Annual)0.31x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.92

Price vs S&P 500 (YTD)-22.22%

Net Profit Margin (TTM)-58.52%

EPS (TTM)$-3.51

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-3.51

EPS (Annual)$-4.19

ROI (Annual)-99.33%

Cash / Share (Quarterly)$26.00

Revenue Growth QoQ (YoY)331.67%

ROA (Last FY)-22.65%

Revenue Growth TTM (YoY)476.71%

EBITD / Share (TTM)$-3.68

ROE (5Y Avg)-152.43%

Operating Margin (TTM)-78.98%

Cash Flow / Share (Annual)$-1.22

P/B Ratio0.67x

P/B Ratio (Quarterly)0.67x

Net Income / Employee (Annual)$-461,000

EV / Revenue (TTM)-1.90x

Net Interest Coverage (TTM)-581.41x

ROA (TTM)-21.38%

EPS Incl Extra (Annual)$-4.19

Current Ratio (Annual)2.58x

Quick Ratio (Quarterly)3.50x

3-Month Avg Trading Volume0.04M

52-Week Price Return-18.95%

Revenue / Employee (TTM)$703,700

Tangible BV / Share (Quarterly)$1.91

P/S Ratio (Annual)1.11x

Asset Turnover (Annual)0.28x

52-Week High$12.74

EPS Excl Extra (Annual)$-4.19

CapEx CAGR (5Y)-25.05%

26-Week Price Return-27.43%

Quick Ratio (Annual)2.53x

13-Week Price Return1.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.59x

Enterprise Value$-101.60M

Asset Turnover (TTM)0.37x

Revenue / Employee (Annual)$575,900

Pretax Margin (Annual)-80.05%

Cash / Share (Annual)$30.36

3-Month Return Std Dev53.76%

Net Income / Employee (TTM)$-411,800

ROE (Last FY)-99.33%

Net Interest Coverage (Annual)-1.08x

EPS Basic Excl Extra (Annual)$-4.19

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.51

ROI (TTM)-39.20%

P/S Ratio (TTM)0.91x

Revenue / Share (Annual)$5.24

Tangible BV / Share (Annual)$3.85

Price vs S&P 500 (52W)-43.31%

Year-to-Date Return-14.06%

5-Day Price Return-6.67%

EPS Normalized (Annual)$-4.19

ROA (5Y Avg)-65.62%

Net Profit Margin (Annual)-80.05%

Month-to-Date Return-8.98%

Cash Flow / Share (TTM)$-2.89

EBITD / Share (Annual)$-4.84

Operating Margin (Annual)-95.92%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-147.11%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.51

P/TBV (Quarterly)0.62x

P/B Ratio (Annual)0.95x

Pretax Margin (TTM)-58.52%

Book Value / Share (Annual)$7.79

Price vs S&P 500 (13W)-6.67%

Beta-0.06x

Revenue / Share (TTM)$3.27

ROE (TTM)-39.20%

52-Week Low$6.47

gGradeA

mGradeC

vgmGradeB

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.20

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XLOXilio Therapeutics, Inc. Common Stock	—	A	C	$7.70
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-activated immunotherapy treatments designed to improve cancer outcomes while minimizing systemic side effects. The company's proprietary platform generates novel I-O molecules that localize anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, and immune cell engagers. This approach aims to optimize therapeutic efficacy while reducing the toxicity associated with conventional immunotherapies.